Drug Information
Side Effects > Zegerid

Zegerid Side Effects

Please note - some side effects for Zegerid may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).


For the consumer

For the professional

Side Effects of Zegerid - for the consumer


Zegerid

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Zegerid:

Diarrhea; headache.

Seek medical attention right away if any of these SEVERE side effects occur when using Zegerid:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); chest pain, dark urine, fast or irregular heartbeat; fever, chills, or sore throat; red, swollen, blistered, or peeling skin; seizures; swelling of the hands, ankles, or feet; unusual bruising or bleeding; unusual or sudden weight increase; unusual tiredness; vision changes; yellowing of the eyes or skin.


Zegerid Powder Packets

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Zegerid Powder Packets:

Diarrhea; headache.

Seek medical attention right away if any of these SEVERE side effects occur when using Zegerid Powder Packets:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); chest pain, dark urine, fast or irregular heartbeat; fever, chills, or sore throat; red, swollen, blistered, or peeling skin; seizures; swelling of the hands, ankles, or feet; unusual bruising or bleeding; unusual or sudden weight increase; unusual tiredness; vision changes; yellowing of the eyes or skin.

Top

For the professional


Zegerid

Omeprazole was generally well tolerated during domestic and international clinical trials in 3096 patients.

In the U.S. clinical trial population of 465 patients, the adverse experiences summarized in Table 11 were reported to occur in 1% or more of patients on therapy with omeprazole. Numbers in parentheses indicate percentages of the adverse experiences considered by investigators as possibly, probably or definitely related to the drug.

Table 11: Adverse Experiences Occurring In 1% or More of Patients on Omeprazole Therapy
Omeprazole
(n = 465)
Placebo
(n = 64)
Ranitidine
(n = 195)
Headache 6.9 (2.4) 6.3 7.7 (2.6)
Diarrhea 3.0 (1.9) 3.1 (1.6) 2.1 (0.5)
Abdominal Pain 2.4 (0.4) 3.1 2.1
Nausea 2.2 (0.9) 3.1 4.1 (0.5)
URI 1.9 1.6 2.6
Dizziness 1.5 (0.6) 0.0 2.6 (1.0)
Vomiting 1.5 (0.4) 4.7 1.5 (0.5)
Rash 1.5 (1.1) 0.0 0.0
Constipation 1.1 (0.9) 0.0 0.0
Cough 1.1 0.0 1.5
Asthenia 1.1 (0.2) 1.6 (1.6) 1.5 (1.0)
Back Pain 1.1 0.0 0.5

Table 12 summarizes the adverse reactions that occurred in 1% or more of omeprazole-treated patients from international double-blind, and open-label clinical trials in which 2,631 patients and subjects received omeprazole.

Table 12: Incidence of Adverse Experiences ≥ 1%; Causal Relationship not Assessed
Omeprazole
(n = 2631)
Placebo
(n = 120)
Body as a Whole, site unspecified
   Abdominal pain 5.2 3.3
   Asthenia 1.3 0.8
Digestive System
   Constipation 1.5 0.8
   Diarrhea 3.7 2.5
   Flatulence 2.7 5.8
   Nausea 4.0 6.7
   Vomiting 3.2 10.0
   Acid regurgitation 1.9 3.3
Nervous System/Psychiatric
   Headache 2.9 2.5

A controlled clinical trial was conducted in 359 critically ill patients, comparing Zegerid 40  mg/1680 mg suspension once daily to I.V. cimetidine 1200 mg/day for up to 14 days. The incidence and total number of AEs experienced by ≥ 3% of patients in either group are presented in Table 13 by body system and preferred term.

Table 13: Number (%) of Critically Ill Patients with Frequently Occurring (≥ 3%) Adverse Events by Body System and Preferred Term

* Clinically significant UGI bleeding was considered an SAE but it is not included in this table.

Zegerid®
(N=178)
Cimetidine
(N=181)
MedDRA
Body System
    Preferred Term
All AEs
n  (%)
All AEs
n  (%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS
   Anaemia NOS 14 (7.9) 14 (7.7)
   Anaemia NOS Aggravated 4 (2.2) 7 (3.9)
   Thrombocytopenia 18 (10.1) 11 (6.1)
CARDIAC DISORDERS
   Atrial Fibrillation 11 (6.2) 7 (3.9)
   Bradycardia NOS 7 (3.9) 5 (2.8)
   Supraventricular Tachycardia 6 (3.4) 2 (1.1)
   Tachycardia NOS 6 (3.4) 6 (3.3)
   Ventricular Tachycardia 8 (4.5) 6 (3.3)
GASTROINTESTINAL DISORDERS *
   Constipation 8 (4.5) 8 (4.4)
   Diarrhoea NOS 7 (3.9) 15 (8.3)
   Gastric Hypomotility 3 (1.7) 6 (3.3)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
   Hyperpyrexia 8 (4.5) 3 (1.7)
   Oedema NOS 5 (2.8) 11 (6.1)
   Pyrexia 36 (20.2) 29 (16.0)
INFECTIONS AND INFESTATIONS
   Candidal Infection NOS 3 (1.7) 7 (3.9)
   Oral Candidiasis 7 (3.9) 1 (0.6)
   Sepsis NOS 9 (5.1) 9 (5.0)
   Urinary Tract Infection NOS 4 (2.2) 6 (3.3)
INVESTIGATIONS
   Liver Function Tests NOS Abnormal 3 (1.7) 6 (3.3)
METABOLISM AND NUTRITION DISORDERS
   Fluid Overload 9 (5.1) 14 (7.7)
   Hyperglycaemia NOS 19 (10.7) 21 (11.6)
   Hyperkalaemia 4 (2.2) 6 (3.3)
   Hypernatraemia 3 (1.7) 9 (5.0)
   Hypocalcaemia 11 (6.2) 10 (5.5)
   Hypoglycaemia NOS 6 (3.4) 8 (4.4)
   Hypokalaemia 22 (12.4) 24 (13.3)
   Hypomagnesaemia 18 (10.1) 18 (9.9)
   Hyponatraemia 7 (3.9) 5 (2.8)
   Hypophosphataemia 11 (6.2) 7 (3.9)
PSYCHIATRIC DISORDERS
   Agitation 6 (3.4) 16 (8.8)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
   Acute Respiratory Distress Syndrome 6 (3.4) 7 (3.9)
   Nosocomial Pneumonia 20 (11.2) 17 (9.4)
   Pneumothorax NOS 1 (0.6) 8 (4.4)
   Respiratory Failure 3 (1.7) 6 (3.3)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
   Decubitus Ulcer 6 (3.4) 5 (2.8)
   Rash NOS 10 (5.6) 11 (6.1)
VASCULAR DISORDERS
   Hypertension NOS 14 (7.9) 6 (3.3)
   Hypotension NOS 17 (9.6) 12 (6.6)

Additional adverse experiences occurring in < 1% of patients or subjects in domestic and/or international trials conducted with omeprazole, or occurring since the drug was marketed, are shown below within each body system. In many instances, the relationship to omeprazole was unclear.

Body As a Whole

Allergic reactions, including, rarely, anaphylaxis, fever, pain, fatigue, malaise, abdominal swelling.

Cardiovascular

Chest pain or angina, tachycardia, bradycardia, palpitation, elevated blood pressure, and peripheral edema.

Gastrointestinal

Pancreatitis (some fatal), anorexia, irritable colon, flatulence, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, dry mouth, stomatitis. During treatment with omeprazole, gastric fundic gland polyps have been noted rarely. These polyps are benign and appear to be reversible when treatment is discontinued.

Gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term treatment with omeprazole. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.

Hepatic

Mild and, rarely, marked elevations of liver function tests [ALT (SGPT), AST (SGOT), γ-glutamyl transpeptidase, alkaline phosphatase, and bilirubin (jaundice)]. In rare instances, overt liver disease has occurred, including hepatocellular, cholestatic, or mixed hepatitis, liver necrosis (some fatal), hepatic failure (some fatal), and hepatic encephalopathy.

Metabolic/Nutritional

Hyponatremia, hypoglycemia, and weight gain.

Musculoskeletal

Muscle cramps, myalgia, muscle weakness, joint pain, and leg pain.

Nervous System/Psychiatric

Psychic disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, tremors, apathy, somnolence, anxiety, dream abnormalities; vertigo; paresthesia; and hemifacial dysesthesia.

Respiratory

Epistaxis, pharyngeal pain.

Skin

Rash and rarely, cases of severe generalized skin reactions including toxic epidermal necrolysis (TEN; some fatal), Stevens-Johnson syndrome, and erythema multiforme (some severe); purpura and/or petechiae (some with rechallenge); skin inflammation, urticaria, angioedema, pruritus, photosensitivity, alopecia, dry skin, and hyperhidrosis.

Special Senses

Tinnitus, taste perversion.

Ocular

Blurred vision, ocular irritation, dry eye syndrome, optic atrophy, anterior ischemic optic neuropathy, optic neuritis and double vision.

Urogenital

Interstitial nephritis (some with positive rechallenge), urinary tract infection, microscopic pyuria, urinary frequency, elevated serum creatinine, proteinuria, hematuria, glycosuria, testicular pain, and gynecomastia.

Hematologic

Rare instances of pancytopenia, agranulocytosis (some fatal), thrombocytopenia, neutropenia, leukopenia, anemia, leucocytosis, and hemolytic anemia have been reported.

The incidence of clinical adverse experiences in patients greater than 65 years of age was similar to that in patients 65 years of age or less.

Additional adverse reactions that could be caused by sodium bicarbonate, include metabolic alkalosis, seizures, and tetany.

Top

More resources:

Drugs.com Zegerid

MedFacts Zegerid

Micromedex Zegerid - Includes detailed dosage instructions.

FDA Zegerid

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.


MedNotes
Advertisement